Ionis Pharmaceuticals (IONS) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Citi Upgrades Ionis Pharmaceuticals (IONS) to Neutral
May 4, 2023 6:27 AM EDTCiti analyst David Lebowitz upgraded Ionis Pharmaceuticals (NASDAQ: IONS) from Sell to Neutral with a price target of $36.00 (from $30.00).
The analyst comments "Upgrading to Neutral, Raising PT to $36 (+$6) Eplontersen prospects in ATTR is a key driver for LT growth. Recently reported full data continues to suggest eplontersen is... More
